Robert F. Kennedy Jr. may soon be America's top pharmaceutical regulator. That is cause for concern in Seattle’s biotech ...
Zentalis Pharmaceuticals, Inc.’s ZNTL share price has dipped by 21.25%, which has investors questioning if this is right time ...
MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...
Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve ...
The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...
Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer.
Merck and Eisai said on Friday a combination of their cancer therapies failed to extend the lives of patients with a type of ...
GSK plc (LSE/NYSE: GSK) today announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...
Hosted on MSN13d
Cancer rate sees an alarming rise in young females; Know the most common cancers in womenSquamous cell carcinoma (SCC): A type of skin cancer that starts in the ... This is why it's important to get regular ...
Many people become confused over the definitions of a primary vs secondary or second cancer. Primary cancer is defined as the original site (organ or tissue) where cancer began. In contrast, a second ...
Endometrial cancer (EC) is the most common female genital malignancy in the USA. Most carcinomas arising from the uterus are estrogen dependent and are associated with obesity and hypertension ...
Expert Rev Anticancer Ther. 2012;12(1):41-49. © 2012 Expert Reviews Ltd. Uterine serous cancer (USC) is a highly aggressive variant of endometrial cancer. USC is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback